Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study ; volume:23 ; number:1 ; day:5 ; month:2 ; year:2021 ; pages:1-12 ; date:12.2021
Arthritis Research & Therapy ; 23, Heft 1 (5.2.2021), 1-12, 12.2021
- Urheber
-
Kay, Jonathan
Jaworski, Janusz
Wojciechowski, Rafal
Wiland, Piotr
Dudek, Anna
Krogulec, Marek
Jeka, Slawomir
Zielinska, Agnieszka
Trefler, Jakub
Bartnicka-Maslowska, Katarzyna
Krajewska-Wlodarczyk, Magdalena
Klimiuk, Piotr A.
Lee, Sang Joon
Bae, Yun Ju
Yang, Go Eun
Yoo, Jae Kyoung
Furst, Daniel E.
Keystone, Edward
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13075-020-02394-7
- URN
-
urn:nbn:de:101:1-2021032819535501833152
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kay, Jonathan
- Jaworski, Janusz
- Wojciechowski, Rafal
- Wiland, Piotr
- Dudek, Anna
- Krogulec, Marek
- Jeka, Slawomir
- Zielinska, Agnieszka
- Trefler, Jakub
- Bartnicka-Maslowska, Katarzyna
- Krajewska-Wlodarczyk, Magdalena
- Klimiuk, Piotr A.
- Lee, Sang Joon
- Bae, Yun Ju
- Yang, Go Eun
- Yoo, Jae Kyoung
- Furst, Daniel E.
- Keystone, Edward
- SpringerLink (Online service)
Ähnliche Objekte (12)
AVT02: An Adalimumab Biosimilar
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Correction to: AVT02: An Adalimumab Biosimilar
Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
AVT02: An Adalimumab Biosimilar
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Correction to: AVT02: An Adalimumab Biosimilar
Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
AVT02: An Adalimumab Biosimilar
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Correction to: AVT02: An Adalimumab Biosimilar
Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases